Table 2 Genetic instability of the epithelium and stroma in colorectal tumours.
| MSI+/informative cases (%)* | p Value† | LOH+/informative cases (%)* | p Value† | ||||
|---|---|---|---|---|---|---|---|
| Epithelium | Stroma | Epithelium | Stroma | ||||
| NCI markers | Control | 0/10 (0) | 0/10 (0) | NS | 0/10 (0) | 0/10 (0) | NS |
| HP | 1/34 (2.9)a | 1/34 (2.9) | NS | 0/34 (0)j,k | 0/34 (0) | NS | |
| TA‐L | 2/38 (5.3)b | 0/38 (0) | NS | 3/38 (7.9)l | 0/38 (0)w | NS | |
| TA‐H | 2/51(3.9)c | 1/51 (2.0) | NS | 6/51 (11.8)k | 1/51 (2.0) | NS | |
| CA | 9/41 (22.0)a,b,c | 1/41 (2.4) | 0.0069 | 10/41 (24.4)j,k | 4/41 (9.8)w | NS | |
| Chr17 markers | Control | 0/10 (0) | 0/10 (0) | NS | 0/10 (0)m | 0/10 (0) | NS |
| HP | 1/34 (2.9)d | 0/34 (0) | NS | 1/34 (2.9)n | 1/34 (2.9) | NS | |
| TA‐L | 1/38 (2.6)e | 0/38 (0) | NS | 1/38 (2.6)o,p | 2/38 (5.3) | NS | |
| TA‐H | 5/51 (9.8) | 2/51 (3.9) | NS | 9/51 (17.6)n,p,q | 3/51(5.9) | NS | |
| CA | 8/41 (19.5)d,e | 3/41 (7.3) | NS | 21/41 (51.2)m,o,q | 4/41(9.8) | <0.0001 | |
| Total markers‡ | Control | 0/10 (0)f | 0/10 (0) | NS | 0/10 (0)r | 0/10 (0) | NS |
| HP | 3/34 (8.8)g | 1/34 (2.9) | NS | 1/34 (2.9)s,t | 1/34 (2.9)x | NS | |
| TA‐L | 2/38 (5.3)h | 2/38 (5.3) | NS | 5/38 (13.2)u | 2/38 (5.3) | NS | |
| TA‐H | 7/51(13.7)i | 3/51 (5.9) | NS | 14/51 (27.5)t,v | 3/51 (5.9) | 0.0035 | |
| CA | 14/41 (34.2)f,g,h,i | 3/41 (7.3) | 0.0027 | 25/41 (61.0)r,s,u,v | 7/41 (17.1)x | <0.0001 | |
*Percentage microsatellite instability (MSI) or loss of heterozygosity (LOH)+/informative case.
†Significant difference between epithelium and stroma.
‡Total markers: National Cancer Institute (NCI) markers, chromosome 17 (Chr17) markers, and MYCL.
HP, hyperplastic polyp; TA‐L, tubular adenoma with low grade dysplasia; TA‐H, tubular adenoma with high grade dysplasia; Ca, adenocarcinoma.
a, b, d, e, f, i, k, l, n, p, w, x, p<0.05; c, g, p<0.01; h, j, m, t, v , p<0.005; q, r, p<0.001; o, s, u, p<0.0001.